Literature DB >> 22908861

Diagnostic criteria in IBS: useful or not?

Fermín Mearin1, Brian E Lacy.   

Abstract

There are a number of reasons to establish the accurate diagnosis of irritable bowel syndrome (IBS): to relieve patient uncertainty; to avoid adverse effects of unnecessary medications or treatments; to avoid unnecessary diagnostic procedures and surgeries; to conserve limited healthcare resources; and, of course, to initiate the most appropriate treatment. However, making the diagnosis of IBS remains difficult because it is clinically heterogeneous, no biological marker to detect it exists, many other diseases share the same clinical manifestations and it is often difficult for both physicians and patients to accept the uncertainty of a symptom-based diagnosis. Different diagnostic criteria have been developed during the last 4 decades but none have proved to be an ideal method of accurately diagnosing IBS. Just as importantly, physicians are frequently unaware of published guidelines or consciously ignore these diagnostic criteria. Most clinicians still believe IBS is a diagnosis of exclusion and not a positive diagnosis based on history, physical examination, use of published diagnostic criteria such as the Rome III criteria, and the absence of alarm features. In the sections to follow we will address the inherent difficulties of diagnosing IBS, highlight the importance of symptom-based diagnoses to help reign in soaring healthcare costs, and discuss future strategies that may enable a more cost-efficient diagnosis of IBS.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22908861     DOI: 10.1111/j.1365-2982.2012.01992.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  15 in total

Review 1.  Current and emerging pharmacotherapeutic options for irritable bowel syndrome.

Authors:  Jose L Barboza; Nicholas J Talley; Baharak Moshiree
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

2.  Questionnaire on Irritable Bowel Syndrome and Symptom Management Among Endurance Athletes Is Valid and Reliable.

Authors:  Lauren A Killian; Karen M Chapman-Novakofski; Soo-Yeun Lee
Journal:  Dig Dis Sci       Date:  2018-09-19       Impact factor: 3.199

3.  Irritable Bowel Syndrome: Pain in Spain.

Authors:  Fermín Mearin
Journal:  Am J Gastroenterol       Date:  2017-11-14       Impact factor: 10.864

Review 4.  Irritable bowel syndrome: a clinical review.

Authors:  Rosa L S Soares
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 5.  Natural polyphenols for the prevention of irritable bowel syndrome: molecular mechanisms and targets; a comprehensive review.

Authors:  Nazanin Momeni Roudsari; Naser-Aldin Lashgari; Saeideh Momtaz; Mohammad Hosein Farzaei; André M Marques; Amir Hossein Abdolghaffari
Journal:  Daru       Date:  2019-07-04       Impact factor: 3.117

6.  [Abdominal spasms, meteorism, diarrhea: fructose intolerance, lactose intolerance or IBS?].

Authors:  Margaritha Litschauer-Poursadrollah; Sabine El-Sayad; Felix Wantke; Christina Fellinger; Reinhart Jarisch
Journal:  Wien Med Wochenschr       Date:  2012-12-07

Review 7.  Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review.

Authors:  Kjetil Gundro Brurberg; Marita Sporstøl Fønhus; Lillebeth Larun; Signe Flottorp; Kirsti Malterud
Journal:  BMJ Open       Date:  2014-02-07       Impact factor: 2.692

8.  The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials.

Authors:  L Chang; A J Lembo; B J Lavins; S J Shiff; X Hao; J G Chickering; X D Jia; M G Currie; C B Kurtz; J M Johnston
Journal:  Aliment Pharmacol Ther       Date:  2014-10-13       Impact factor: 8.171

9.  Drug development for the irritable bowel syndrome: current challenges and future perspectives.

Authors:  Fabrizio De Ponti
Journal:  Front Pharmacol       Date:  2013-02-01       Impact factor: 5.810

Review 10.  The epidemiology of irritable bowel syndrome.

Authors:  Caroline Canavan; Joe West; Timothy Card
Journal:  Clin Epidemiol       Date:  2014-02-04       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.